Given the elevated expression of the PIEZO1‐YAP1‐CTGF axis, which serves as a linchpin in tumour development and encourages peritoneal metastasis, therapeutically targeting this oncogenic pathway could effectively halt the progression from IM to GC. Here, CCN2 is linked to gastric cancer.